Drug
Chf 4226 Pmdi
Chf 4226 Pmdi: highest development phase Phase 1, developed by Chiesi Farmaceutici. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Chiesi Farmaceutici
Trials
| Drug | Phase | Indication |
|---|---|---|
| CHF 4226 pMDI NCT00777595 | Phase 1 | Chronic Obstructive Pulmonary Disease |
Latest
No recent events.
Follow Chf 4226 Pmdi on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.